Form 4: Adicet Bio Director Andrew Sinclair Receives Significant Equity Grants

Adicet Bio, Inc. Director Andrew Sinclair was granted 5,900 Restricted Stock Units and options to purchase 26,400 shares of common stock on June 11, 2025, as part of his compensation.

Summary

• Andrew Sinclair, a Director of Adicet Bio, Inc. (ACET), reported the acquisition of equity securities.
• On June 11, 2025, Mr. Sinclair was granted 5,900 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• Following this transaction, Mr. Sinclair directly beneficially owns 17,700 shares of Common Stock.
• Additionally, on June 11, 2025, Mr. Sinclair was granted stock options to acquire 26,400 shares of Common Stock with an exercise price of $0.78 per share.
• These stock options have an expiration date of June 10, 2035.
• Both the RSUs and stock options are subject to vesting, which occurs in full on the earlier of (i) the first anniversary of the grant date (June 11, 2025) or (ii) the date of the next annual meeting of stockholders following the grant date, contingent upon Mr. Sinclair's continued service on the Issuer's board of directors.

Sentiment

Score: 7

Explanation: The filing reports routine equity grants to a director, which is a standard compensation practice and aligns management's interests with shareholders, indicating a neutral to slightly positive sentiment.

Positives

• The grant of Restricted Stock Units and stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Risks

• The value of the granted equity awards is subject to the future performance of Adicet Bio, Inc.'s stock price, which carries inherent market risk.
• Vesting of the RSUs and options is contingent on the director's continued service, meaning the awards could be forfeited if service ceases before vesting.

Future Outlook

The vesting schedule for the granted RSUs and stock options indicates a future commitment from the director, with full vesting contingent on continued service through the first anniversary of the grant date or the next annual meeting, whichever is earlier.

Industry Context

Equity grants, including Restricted Stock Units and stock options, are a common and standard form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice is designed to align the interests of company leadership with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as part of director compensation is a widely adopted practice across the biotechnology and broader corporate sectors, consistent with global benchmarks for executive and board remuneration.
• The vesting conditions, tied to continued service and a specific timeframe (one year or next annual meeting), are typical for such grants, aiming to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The transaction involves Andrew Sinclair, a Director of Adicet Bio, Inc., receiving equity compensation from the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grants are part of the compensation for a key management figure (director), incentivizing their continued service and performance.

Next Steps

• The granted Restricted Stock Units and stock options will vest based on the specified conditions (earlier of first anniversary of grant date or next annual meeting), subject to Andrew Sinclair's continued service on the board.

Key Dates

Keywords

Adicet Bio, ACET, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership